# of Displayed Technologies: 10 / 82

Applied Category Filter (Click To Remove): Life Sciences


Categories

Biomimetic vitreous substitute with ocular drug delivery
TS-044490 — Methods and compositions for an antioxidant releasing hydrogel vitreous substitute
The vitreous humor is a fragile, transparent tissue between the lens and the retina of the eye that maintains the shape of the eye, acts as a shock absorber, and enables nutrient diffusion to ocular tissues. The vitreous also plays a key role in oxygen homeostasis. Over time, the vitreous degrades…
  • College: College of Engineering (COE)
  • Inventors: Reilly, Katelyn; Reilly, Matthew; Tram, Nguyen "Archie"
  • Licensing Officer: Flammang, Ann Marie

Nanoparticle Composition for Nucleic Acid Delivery
TS-044109 — Lipid nanoparticles (LNs) usable for the delivery of therapeutic compositions, including, but not limited to nucleic acids (NAs).
Nucleic Acid (NA) based therapies are used to inhibit gene expression. Lipid nanoparticles (LNs) are capable of carrying these therapies into cells. However, this delivery requires overcoming several physiological barriers. For instance, one barrier is the acidic endosome conditions within the cel…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Dahlman, Jason "Jay"

Cold responsive nanoparticles for overcoming cancer drug resistance
TS-043509 — A cold-responsive nanoparticle that quickly disassembles upon ice cooling leading to intracellular burst release of a chemotherapeutic drug in seconds
Stimuli-responsive nanoparticles (NPs) hold great promise for controlling drug release inside cancer cells. An obstacle to the effectiveness of this approach to chemotherapeutic drug delivery is the rapid expulsion of the delivered drug catalyzed by efflux pumps in the cell's plasma membrane. …
  • College: College of Engineering (COE)
  • Inventors: He, Xiaoming "Shawn"; Wang, Hai
  • Licensing Officer: Norris, Francis "Frank"

A Bi-layered Capsule for Sustainable Delivery of Protein Therapeutics
TS-042858 — A biodegradable drug delivery system for the treatment of disease, especially ophthalmic diseases including age-related macular degeneration (AMD). The device will be injected and can control drug release for at least 6 months following the initial injection.
Retinal diseases can be extremely difficult to monitor once procedures have been initiated. AMD is the fourth most common causes of blindness and requires monthly injections to manage the effects of the disease and prevent permanent blindness. However, receiving recurrent injections can potentiall…
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Coutinho da Silva, Marco; Lannutti, John; Ohr, Matthew; Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Engineered Cells for Treatment of Animal Metabolic Disorders
TS-041976 — The implantation of engineered thermogenic cells for treating metabolic disease and obesity in animals.
Obesity remains one of the main underlying causes for many malignancies in domestic animals such as cats, dogs, and horses. From a veterinary perspective, obesity dramatically increases the risk of cancer, one of the leading causes of death in domesticated animals. Other diseases correlated with o…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana
  • Licensing Officer: Flammang, Ann Marie

miRNA Biomarkers for Diagnosis and Prediction of Radiation Induced Injury
TS-041968 — A minimally invasive procedure to determine radiation toxicity in victims of nuclear events or radiation therapy patients.
The lack of a reliable radiation biodosimeter has been a major barrier to medical decision-making regarding the triage and treatment of persons - civilians, soldiers and first-time responders - who might be at risk for developing acute radiation syndromes (ARS) following nuclear events (e.g. nucle…
  • College: College of Medicine (COM)
  • Inventors: Jacob, Naduparambil "Naduparambil"
  • Licensing Officer: Norris, Francis "Frank"

Junctional Tourniquet for Groin and Axillary Regions
TS-041808 — A tourniquet with a ratcheting lock to keep pressure on wounds in the groin and axillary regions. Hemostasis can be achieved while the patient is still in the field.
Patients with blood loss in the field need to be treated immediately to prevent ongoing blood loss, shock, and death; bleeding from extremity and junctional wounds is the leading cause of potentially preventable death from penetrating injuries. Direct manual pressure is effective for the initial c…
  • College: OSU Wexner Medical Center
  • Inventors: McElroy, James; Graham, Nadi; Nocera, Tanya
  • Licensing Officer: Flammang, Ann Marie

Papverine Derivatives as Metabolic Radiosensitizers
TS-041504 — Papverine derivatives that can be used as metabolic radiosensitizers. The compounds make cancer cells more sensitive to radiation therapy without the concomitant toxicity issues that can occur as a side-effect of papverine.
Radiation therapy is a common treatment for cancerous tumors. Different types of cancer cells have varying sensitivity to radiation therapy, and some are almost unaffected by treatment. For example, breast cancer, glioblastoma, bladder cancer, and soft-tissue carcinoma do not react well to radiati…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Mitton-Fry, Mark; Papandreou, Ioanna; Vibhute, Sandip
  • Licensing Officer: Paschall, Christopher

Multi-Functional Cancer Drug Delivery Nanodevice for Precision Medicine
TS-041485 — Using the scaffolded DNA origami molecular self-assembly process, a manufactured DNA nanostructure can be created that circumvents MDR1/MRP-1 protein efflux pump-mediated multi-drug resistance in cancer cells to deliver clinically significant concentrations of chemotherapeutics.
The majority of human cancers remain incurable, in many cases this is due to innate or developed multi-drug resistance (MDR). Current therapeutics used in treatment are inadequate in light of such resistance, and more robust approaches must be found to circumvent these responses and deliver therap…
  • College: College of Engineering (COE)
  • Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
  • Licensing Officer: Paschall, Christopher

Show More Technologies

Loading icon